|
1
|
Rong S, Wan D, Fan Y, Liu S, Sun K, Huo J,
Zhang P, Li X, Xie X, Wang F, et al: Amentoflavone affects
epileptogenesis and exerts neuroprotective effects by inhibiting
NLRP3 inflammasome. Front Pharmacol. 10:8562019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Juvale IIA and Che Has AT: Possible
interplay between the theories of pharmacoresistant epilepsy. Eur J
Neurosci. 53:1998–2026. 2021. View Article : Google Scholar
|
|
3
|
Xiao D, Lv J, Zheng Z, Liu Y, Zhang Y, Luo
C, Qi L, Qin B and Liu C: Mechanisms of microRNA 142 in
mitochondrial autophagy and hippocampal damage in a rat model of
epilepsy. Int J Mol Med. 47:982021. View Article : Google Scholar
|
|
4
|
González-H G, Contreras-García IJ,
Sánchez-Huerta K, Queiroz CM, Gallardo Gudiño LR,
Mendoza-Torreblanca JG and Zamudio SR: Levetiracetam reduced the
basal excitability of the dentate gyrus without restoring impaired
synaptic plasticity in rats with temporal lobe epilepsy. Brain Sci.
10:E6342020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guiard BP and Di Giovanni G: Central
serotonin-2A (5-HT2A) receptor dysfunction in depression and
epilepsy: The missing link? Front Pharmacol. 6:462015. View Article : Google Scholar :
|
|
6
|
Fisher RS, van Emde Boas W, Blume W, Elger
C, Genton P, Lee P and Engel J Jr: Epileptic seizures and epilepsy:
Definitions proposed by the International League Against Epilepsy
(ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia.
46:470–472. 2005. View Article : Google Scholar
|
|
7
|
Baroli G, Sanchez JR, Agostinelli E,
Mariottini P and Cervelli M: Polyamines: The possible missing link
between mental disorders and epilepsy (Review). Int J Mol Med.
45:3–9. 2020.
|
|
8
|
Perucca E, Brodie MJ, Kwan P and Tomson T:
30 years of second-generation antiseizure medications: Impact and
future perspectives. Lancet Neurol. 19:544–556. 2020. View Article : Google Scholar
|
|
9
|
Wang Y and Chen Z: An update for epilepsy
research and antiepileptic drug development: Toward precise circuit
therapy. Pharmacol Ther. 201:77–93. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Löscher W, Potschka H, Sisodiya SM and
Vezzani A: Drug resistance in epilepsy: Clinical impact, potential
mechanisms, and new innovative treatment options. Pharmacol Rev.
72:606–638. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
West PJ, Saunders GW, Remigio GJ, Wilcox
KS and White HS: Antiseizure drugs differentially modulate θ-burst
induced long-term potentiation in C57BL/6 mice. Epilepsia.
55:214–223. 2014. View Article : Google Scholar :
|
|
12
|
Vezzani A, Fujinami RS, White HS, Preux
PM, Blümcke I, Sander JW and Löscher W: Infections, inflammation
and epilepsy. Acta Neuropathol. 131:211–234. 2016. View Article : Google Scholar :
|
|
13
|
Espinosa-Garcia C, Zeleke H and Rojas A:
Impact of stress on epilepsy: Focus on neuroinflammation-A mini
review. Int J Mol Sci. 22:40612021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shao BZ, Xu ZQ, Han BZ, Su DF and Liu C:
NLRP3 inflammasome and its inhibitors: A review. Front Pharmacol.
6:2622015. View Article : Google Scholar
|
|
15
|
Wu C, Zhang G, Chen L, Kim S, Yu J, Hu G,
Chen J, Huang Y, Zheng G and Huang S: The role of NLRP3 and IL-1β
in refractory epilepsy brain injury. Front Neurol. 10:14182020.
View Article : Google Scholar
|
|
16
|
de Brito Toscano EC, Vieira ÉL, Dias BB,
Caliari MV, Gonçalves AP, Giannetti AV, Siqueira JM, Suemoto CK,
Leite RE, Nitrini R, et al: NLRP3 and NLRP1 inflammasomes are
up-regulated in patients with mesial temporal lobe epilepsy and may
contribute to overexpression of caspase-1 and IL-β in sclerotic
hippocampi. Brain Res. 1752:1472302021. View Article : Google Scholar
|
|
17
|
Kegler A, Caprara AL, Pascotini ET, Arend
J, Gabbi P, Duarte MM, Furian AF, Oliveira MS, Royes LF and Fighera
MR: Apoptotic markers are increased in epilepsy patients: A
relation with manganese superoxide dismutase Ala16Val polymorphism
and deizure type through IL-1β and IL-6 pathways. BioMed Res Int.
2020:62504292020. View Article : Google Scholar
|
|
18
|
Liu R, Wu S, Guo C, Hu Z, Peng J, Guo K,
Zhang X and Li J: Ibuprofen exerts antiepileptic and
neuroprotective effects in the rat model of
pentylenetetrazol-induced epilepsy via the COX-2/NLRP3/IL-18
pathway. Neurochem Res. 45:2516–2526. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tran KL, Park YI, Pandya S, Muliyil NJ,
Jensen BD, Huynh K and Nguyen QT: Overview of glucagon-like
peptide-1 receptor agonists for the treatment of patients with type
2 diabetes. Am Health Drug Benefits. 10:178–188. 2017.
|
|
20
|
Koshal P and Jamwal S: An insight review.
Neuropharmacology. 136:271–279. 2018. View Article : Google Scholar
|
|
21
|
Zhu W, Feng PP, He K, Li SW and Gong JP:
Liraglutide protects non-alcoholic fatty liver disease via
inhibiting NLRP3 inflammasome activation in a mouse model induced
by high-fat diet. Biochem Biophys Res Commun. 505:523–529. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu X, Hao M, Liu Y, Ma X, Lin W, Xu Q,
Zhou H, Shao N and Kuang H: Liraglutide ameliorates non-alcoholic
steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis
activation via mitophagy. Eur J Pharmacol. 864:1727152019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cork SC, Richards JE, Holt MK, Gribble FM,
Reimann F and Trapp S: Distribution and characterisation of
Glucagon-like peptide-1 receptor expressing cells in the mouse
brain. Mol Metab. 4:718–731. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Graham DL, Durai HH, Trammell TS, Noble
BL, Mortlock DP, Galli A and Stanwood GD: A novel mouse model of
glucagon-like peptide-1 receptor expression: A look at the brain. J
Comp Neurol. 528:2445–2470. 2020. View Article : Google Scholar :
|
|
25
|
Liu S, Jin Z, Zhang Y, Rong S, He W, Sun
K, Wan D, Huo J, Xiao L, Li X, et al: The glucagon-like peptide-1
analogue liraglutide reduces seizures susceptibility, cognition
dysfunction and neuronal apoptosis in a mouse model of dravet
syndrome. Front Pharmacol. 11:1362020. View Article : Google Scholar
|
|
26
|
Dhillon S: Semaglutide: First global
approval. Drugs. 78:275–284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X, Feng P, Zhang X, Li D, Wang R, Ji
C, Li G and Hölscher C: The diabetes drug semaglutide reduces
infarct size, inflammation, and apoptosis, and normalizes
neurogenesis in a rat model of stroke. Neuropharmacology.
158:1077482019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang YF, Zhang D, Hu WM, Liu DX and Li L:
Semaglutide-mediated protection against Aβ correlated with
enhancement of autophagy and inhibition of apotosis. J Clin
Neurosci. 81:234–239. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang L, Zhang L, Li L and Hölscher C:
Semaglutide is neuro-protective and reduces α-synuclein levels in
the chronic MPTP mouse model of Parkinson's disease. J Parkinsons
Dis. 9:157–171. 2019. View Article : Google Scholar
|
|
30
|
Minkeviciene R, Rheims S, Dobszay MB,
Zilberter M, Hartikainen J, Fülöp L, Penke B, Zilberter Y, Harkany
T, Pitkänen A, et al: Amyloid beta-induced neuronal
hyperexcitability triggers progressive epilepsy. J Neurosci.
29:3453–3462. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan XX, Cai Y, Shelton J, Deng SH, Luo XG,
Oddo S, Laferla FM, Cai H, Rose GM and Patrylo PR: Chronic temporal
lobe epilepsy is associated with enhanced Alzheimer-like
neuropathology in 3xTg-AD mice. PLoS One. 7:e487822012. View Article : Google Scholar
|
|
32
|
Nam HY, Nam JH, Yoon G, Lee JY, Nam Y,
Kang HJ, Cho HJ, Kim J and Hoe HS: Ibrutinib suppresses LPS-induced
neuroinflammatory responses in BV2 microglial cells and wild-type
mice. J Neuroinflammation. 15:2712018. View Article : Google Scholar :
|
|
33
|
Zeng QZ, Yang F, Li CG, Xu LH, He XH, Mai
FY, Zeng CY, Zhang CC, Zha QB and Ouyang DY: Paclitaxel Enhances
the Innate Immunity by Promoting NLRP3 Inflammasome Activation in
Macrophages. Front Immunol. 10:722019. View Article : Google Scholar :
|
|
34
|
Koshal P and Kumar P: Neurochemical
modulation involved in the beneficial effect of liraglutide, GLP-1
agonist on PTZ kindling epilepsy-induced comorbidities in mice. Mol
Cell Biochem. 415:77–87. 2016. View Article : Google Scholar
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
36
|
Zheng Z, Liang P, Hou B, Lu X, Ma Q, Yu X,
Han S, Peng B, Chen T, Liu W, et al: The effect of dipeptidyl
peptidase IV on disease-associated microglia phenotypic
transformation in epilepsy. J Neuroinflammation. 18:1122021.
View Article : Google Scholar :
|
|
37
|
Vezzani A, Balosso S and Ravizza T:
Neuroinflammatory pathways as treatment targets and biomarkers in
epilepsy. Nat Rev Neurol. 15:459–472. 2019. View Article : Google Scholar
|
|
38
|
Swanson KV, Deng M and Ting JP: The NLRP3
inflammasome: Molecular activation and regulation to therapeutics.
Nat Rev Immunol. 19:477–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Birnbaum Y, Tran D, Bajaj M and Ye Y:
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and
inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res
Cardiol. 114:352019. View Article : Google Scholar
|
|
40
|
Safar MM, Shahin NN, Mohamed AF and
Abdelkader NF: Suppression of BACE1 and amyloidogenic/RAGE axis by
sitagliptin ameliorates PTZ kindling-induced cognitive deficits in
rats. Chem Biol Interact. 328:1091442020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhu L, Chen L, Xu P, Lu D, Dai S, Zhong L,
Han Y, Zhang M, Xiao B, Chang L, et al: Genetic and molecular basis
of epilepsy-related cognitive dysfunction. Epilepsy Behav.
104:1068482020. View Article : Google Scholar
|
|
42
|
Lai MC, Lin KM, Yeh PS, Wu SN and Huang
CW: The novel effect of immunomodulator-glatiramer acetate on
epileptogenesis and epileptic seizures. Cell Physiol Biochem.
50:150–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Alomar SY, Gentili A, Zaibi MS, Kępczyńska
MA and Trayhurn P: IL-1β (interleukin-1β) stimulates the production
and release of multiple cytokines and chemokines by human
preadipocytes. Arch Physiol Biochem. 122:117–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen A, Chen Z, Xia Y, Lu D, Yang X, Sun
A, Zou Y, Qian J and Ge J: Liraglutide attenuates NLRP3
inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS
pathway in H9c2 cells. Biochem Biophys Res Commun. 499:267–272.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Luo X, Hu Y, He S, Ye Q, Lv Z, Liu J and
Chen X: Dulaglutide inhibits high glucose-induced endothelial
dysfunction and NLRP3 inflammasome activation. Arch Biochem
Biophys. 671:203–209. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ma J, Shi M, Zhang X, Liu X, Chen J, Zhang
R, Wang X and Zhang H: GLP 1R agonists ameliorate peripheral nerve
dysfunction and inflammation via p38 MAPK/NF-κB signaling pathways
in streptozotocin induced diabetic rats. Int J Mol Med.
41:2977–2985. 2018.PubMed/NCBI
|
